The current valuation score of Inovio Pharmaceuticals Inc is 6.52, ranking 328 out of 389 in the Biotechnology & Medical Research industry. Its current P/E ratio is -0.70, which is -96.46% below the recent high of -0.02 and -131.76% above the recent low of -1.63.
P/E
Relevant data have not been disclosed by the company yet.
P/B
Relevant data have not been disclosed by the company yet.
P/S
Relevant data have not been disclosed by the company yet.
P/CF
Relevant data have not been disclosed by the company yet.